PCM
TVTX icon

Penserra Capital Management’s Travere Therapeutics TVTX Stock Holding History

Penserra Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-79,747
Closed -$3.05M – 1183
2025
Q4 		$3.05M Sell
79,747
-809
-1% -$26.3K 0.04% 309
2025
Q3 		$1.93M Buy
+80,556
New +$1.51M 0.02% 342
2025
Q2 		– Sell
-109,542
Closed -$1.96M – 1136
2025
Q1 		$1.96M Buy
+109,542
New +$2.22M 0.04% 304
2021
Q4 		– Sell
-1,390
Closed -$33K – 1551
2021
Q3 		$33K Buy
1,390
+15
+1% +$276 ﹤0.01% 1166
2021
Q2 		$20K Buy
1,375
+75
+6% +$1.48K ﹤0.01% 1152
2021
Q1 		$32K Buy
1,300
+130
+11% +$3.59K ﹤0.01% 894
2020
Q4 		$31K Buy
1,170
+736
+170% +$17.2K ﹤0.01% 771
2020
Q3 		$8K Buy
+434
New +$8.44K ﹤0.01% 841

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Penserra Capital Management's TVTX Position: Q1 2026 in Review

Penserra Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 79,747 shares — an estimated $3.05M sold.

Penserra Capital Management first reported a position in TVTX in Q3 2020 and held it in 8 quarters. The position peaked at $3.05M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Penserra Capital Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Penserra Capital Management sold 79,747 Travere Therapeutics shares in Q1 2026, an estimated $3.05M.
  • Penserra Capital Management first reported a position in Travere Therapeutics in Q3 2020 and held it in 8 quarters.
  • Penserra Capital Management's Travere Therapeutics position peaked at $3.05M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.